WOK revenueFY2025$9.85M
- FY YoY
- -14.4%
WOK revenue was $9.85M for fiscal 2025 (ended Sep 30, 2025), down 14.4% from fiscal 2024. It rose in 0 of the last 3 fiscal years.
WORK Medical Technology Group LTD (WOK) financials
For fiscal 2025 (ended Sep 30, 2025), WORK Medical Technology Group LTD reported $9.85M of revenue and -$1.07M of net income.
- Revenue, FY2025
- $9.85M
- Revenue growth, YoY
- -14.4%
- Net income, FY2025
- -$1.07M
- Net margin
- -10.9%
- Free cash flow, FY2025
- $4.91M
- EPS, diluted, FY2025
- -$0.04
- Cash
- $4.09M
- P/S
- 0.42
- Market cap
- $4.1M
FY2022FY2025
FY2022FY2025
FY2022FY2025
WOK revenue and earnings growth
WOK net incomeFY2025-$1.07M
WOK net income was -$1.07M for fiscal 2025 (ended Sep 30, 2025), compared with -$3.49M in fiscal 2024.
WOK EPSFY2025-$0.04
WOK diluted EPS was -$0.04 for fiscal 2025 (ended Sep 30, 2025).
WOK free cash flowFY2025$4.91M
WOK free cash flow was $4.91M for fiscal 2025 (ended Sep 30, 2025), compared with -$11.45M in fiscal 2024.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
|---|---|---|---|---|
| Revenue | $9.85M | $11.51M | $13.57M | $19.71M |
| Gross profit | $2.34M | $2.87M | $4.14M | $4.42M |
| Research and development | $435.3K | $302.5K | $301.6K | $183.9K |
| Selling, general and admin | $2.33M | $4.56M | $1.86M | $2.56M |
| Interest expense | $503.5K | $557.6K | $392.7K | $353.0K |
| Pre-tax income | -$1.08M | -$3.67M | $110.4K | $1.11M |
| Income tax | $119.1K | -$125.3K | $47.0K | $169.4K |
| Net income | -$1.07M | -$3.49M | $112.0K | $865.2K |
| EPS, basic | -$0.04 | -$0.27 | $0.01 | $0.07 |
| EPS, diluted | -$0.04 | -$0.27 | $0.01 | $0.07 |
| Diluted shares | 29.0M | 12.7M | 12.5M | 12.5M |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $4.09M | $6.56M | $1.60M | $773.4K |
| Receivables | $615.8K | $1.65M | $3.33M | - |
| Inventory | $2.46M | $3.18M | $4.62M | - |
| Current assets | $20.46M | $20.83M | $22.15M | - |
| Total assets | $33.16M | $36.25M | $29.96M | - |
| Current liabilities | $11.97M | $20.18M | $18.92M | - |
| Short-term debt | $6.39M | $13.32M | $8.84M | - |
| Total liabilities | $11.99M | $20.18M | $18.97M | - |
| Shareholders' equity | $18.34M | $13.19M | $10.99M | $11.19M |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
|---|---|---|---|---|
| Operating cash flow | $6.24M | -$2.23M | $2.21M | -$2.26M |
| Capital expenditures | $1.33M | $9.23M | $455.4K | $2.01M |
| Free cash flow | $4.91M | -$11.45M | $1.75M | -$4.27M |
| Investing cash flow | -$7.61M | -$9.06M | -$583.3K | -$1.35M |
| Financing cash flow | -$898.2K | $15.66M | -$728.7K | $3.57M |
| Depreciation and amortization | $923.1K | $1.41M | $1.60M | $3.26M |
Key ratios
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | -14.4% | -15.2% | -31.2% | - |
| Net income growth, YoY | - | - | -87.1% | - |
| EPS growth, YoY | - | - | -85.7% | - |
| Gross margin | 23.8% | 24.9% | 30.5% | 22.4% |
| Net margin | -10.9% | -30.4% | 0.8% | 4.4% |
| Free cash flow margin | 49.9% | -99.5% | 12.9% | -21.7% |
| Return on equity | -5.8% | -26.5% | 1.0% | 7.7% |
| Return on assets | -3.2% | -9.6% | 0.4% | - |
| Current ratio | 1.71 | 1.03 | 1.17 | - |
Source: XBRL data WORK Medical Technology Group LTD files with the SEC, latest filing dated Jan 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
WOK peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| WOK | $9.85M | -14.4% | -$1.07M | -10.9% | $4.1M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $127.56B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.03B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $64.70B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.17B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $52.27B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.66B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $31.50B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $27.34B |
WOK FAQ
9 questionsWhat is WOK revenue?
WORK Medical Technology Group LTD (WOK) reported $9.85M of revenue for fiscal 2025 (ended Sep 30, 2025). That is down 14.4% from the year before.Is WOK profitable?
No. WORK Medical Technology Group LTD reported a net loss of $1.07M for fiscal 2025 (ended Sep 30, 2025).How much cash and debt does WOK have?
WORK Medical Technology Group LTD reported $4.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is WOK revenue growing?
WORK Medical Technology Group LTD's revenue changed -14.4% in fiscal 2025, to $9.85M.What is WOK gross margin?
WORK Medical Technology Group LTD's gross profit was $2.34M on $9.85M of revenue for fiscal 2025 (ended Sep 30, 2025), a gross margin of 23.8%.What is WOK free cash flow?
WORK Medical Technology Group LTD generated $4.91M of free cash flow for fiscal 2025 (ended Sep 30, 2025), which is operating cash flow of $6.24M less capital expenditures.What is WOK earnings per share?
Diluted earnings per share were -$0.04 for fiscal 2025 (ended Sep 30, 2025), from SEC filings, restated for any stock split those filings show.When did WOK last report financial results?
The latest statements here come from WORK Medical Technology Group LTD's 20-F filed on Jan 30, 2026, covering the period ended Sep 30, 2025.Where does this WOK financial data come from?
Quantisnow builds these statements from the structured XBRL data WORK Medical Technology Group LTD files with the SEC. It is provided for information only and is not investment advice.